• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1112723 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
5 E* A# E$ I  u# f' K) g: J$ n- yNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
0 B( S" ]8 R; h/ F! y+ Author Affiliations+ h2 [: Z8 F; E- u; ?& c3 X- G* z

" y( Y. Z4 u, g" ~1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) X6 d9 Z% r8 T3 Y0 M: ]8 ]
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
. i! u+ A! b% V( `: V. U! [3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 F9 ^) L  n: L4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
8 x- e( I2 {1 I+ R5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, [' a' j: b- h* A) C6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 3 h6 x8 G8 t3 `1 J* ?4 u% h
7Kinki University School of Medicine, Osaka 589-8511, Japan
! d* d  B) A7 [' v% C3 r: e% y8Izumi Municipal Hospital, Osaka 594-0071, Japan
, W$ @3 }+ T9 `9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
/ I% U3 P$ e- c7 [3 q8 XCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; j% O7 B6 p# U1 w" I
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 5 a8 L5 [( o  g0 P! J! b

# X( f) Y5 F" P9 Y* B
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
( f) F* ^- k; h! h' o6 }% K0 M
3 N5 p  N5 s  K% SAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato   l& Q' D: |, l4 j% k4 x1 U

+ G7 F& T& Y7 j+ Q) u4 Q- J9 }Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  ' m1 k7 J, b' Z% G# q; y7 N
; T. c- ]1 u+ s0 R
Published online on: Thursday, December 1, 2011
7 i! g, j$ W8 F6 [1 {7 s
! v4 |4 Q2 `. ^* D& z1 Y! LDoi: 10.3892/ol.2011.507 " h' s- x: W0 l' `/ b' E4 C' _" p

1 A6 m! B5 Q. d$ |Pages: 405-410
  L5 S  ?0 T& e: w# H* v; A) Q7 E
% q8 ?/ ~7 ^% j' u, f' F1 ~& g% EAbstract:! G' p0 N6 A8 Z8 K7 v! d
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
5 Y4 \- k% ?- u' k : X3 J7 U6 l( |. q- I
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
; Y, Q1 N- n, h9 dF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 % N0 y% J. `# N! m) O( Y; v
+ Author Affiliations( z! a6 l. b- j; @6 [# S! b
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 2 A: s7 Z. i# j
2Department of Thoracic Surgery, Kyoto University, Kyoto
, k7 V. X3 h' Q# [/ z; v3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
* v: L, a  `& z3 c: k+ j&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp . d" `3 D' l" D7 c
Received September 3, 2010.
5 Y1 S: ]0 J9 I0 vRevision received November 11, 2010. / Y/ C9 p8 T" j" P* T3 `8 B
Accepted November 17, 2010.
! S" C0 C- s, N5 w3 ~: d$ E7 ]Abstract- d. \. D7 k7 \, @7 @* J
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. ( U/ v9 X0 E) B* V( n
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. ( u5 {" v. |# @
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 5 @; v# }  W2 u! f; k3 J* e
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
0 t9 h% b. Q4 T+ H
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。- `' A3 L1 q& D3 c* d& l( |9 X
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
0 ~) b$ t- _& Q/ A
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy9 U/ }6 b9 K$ r. g; k$ a; V
http://clinicaltrials.gov/ct2/show/NCT01523587
( U7 U+ x( `( U3 M! T
7 A/ E+ P) ?! b* S5 O2 I7 IBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC( _6 g: G+ e: A& F3 E3 H% S0 b  J
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 0 Q" X8 t! c- |; [/ Z' t

/ l3 G: y+ G8 U( m4 R* ^* E9 G从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。% g. e' w0 Z+ |9 W4 z) z& P
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
: \! G( S: A7 e) G8 b+ Z# t2 e从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。: s2 B5 P3 z) R1 R4 x5 F' O3 A8 S
至今为止,未出 ...

9 S0 {" T5 l! N- O没有副作用是第一追求,效果显著是第二追求。
$ M: @$ O% @7 a) W/ f4 V不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表